Thr13
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.4
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Thr13  -  CK2A1 (human)

Site Information
PsRARVytDVNtHRP   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 31012808

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 ) , mutation of modification site ( 2 )
Disease tissue studied:
HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 )
Relevant cell line - cell type - tissue:

Upstream Regulation
Putative in vivo kinases:
Akt1 (human) ( 2 )
Kinases, in vitro:
Akt1 (human) ( 2 )
Treatments:
AZD8055 ( 2 ) , siRNA ( 2 )

Downstream Regulation
Effects of modification on biological processes:
transcription, induced ( 2 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Nguyen le XT, Mitchell BS (2013) Akt activation enhances ribosomal RNA synthesis through casein kinase II and TIF-IA. Proc Natl Acad Sci U S A 110, 20681-6
24297901   Curated Info

3

Possemato A (2007) CST Curation Set: 2451; Year: 2007; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P
Curated Info